DAVID GRANOVSKY

Posts Tagged ‘biotech’

Virgin Founder Ready to Launch Stem Cell Bank

In BUSINESS OF STEM CELLS on April 26, 2010 at 7:33 pm

Now, even Sir Richard see’s the future! -David

https://i1.wp.com/www.puddleofred.com/blog/wp-content/uploads/2009/12/Virgin.Galactic.Richard.Branson.jpg

On Thursday Virgin founder Sir Richard Branson geared up to launch his stem-cells and biotech business. The new venture allows parents the ability to store the cells from their child’s umbilical cord.

Scientists believe the cells are useful to treat conditions such as Parkinson’s disease and cancer.
According to BBC reports, many parents of new born children have already used stem-cell storage. The parents are provided with collection kits at the time of birth of their child. The kits are then taken for processing and storage to companies who deal in the business.
Stem-cell storage saves human blood from the placenta or umbilical cord after birth. This blood is rich in hematopoietic stem cells, which are capable of adapting in the body and replacing damaged or diseased cells.
The controversial procedure is gaining popularity in the United States with many private firms intervening into the business. Many celebrities have also opted for cord blood registration.

Virgin Founder Ready to Launch Stem Cell Bank.

Excellent SC Mobilization + Safety Profile for TG-0054

In BUSINESS OF STEM CELLS on September 28, 2009 at 9:21 pm

Excellent SC Mobilization + Safety Profile for TG-0054

TAIPEI, Taiwan, Sept. 28 /PRNewswire-Asia/ — TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated.

The trial was a randomized, double-blind, placebo-controlled, single intravenous dose study including 64 healthy volunteers in US, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG-0054 in 8 cohorts. The mobilized stem and progenitor cells peaked at 4-6 hours following one single intravenous dose.

“We are greatly encouraged by the phase 1 study results which indicates that TG-0054 has the potential to be used alone, not in combination with G- CSF, for allogenic or autologous stem cell transplantation in cancer patients. This should greatly reduce the hospital and other associated cost for such a procedure. Importantly, the activity and safety profile in the phase 1 study will support our future development of TG-0054 in chemosensitization and tissue ischemia, including myocardial infarction, stroke and severe intermittent claudication. Our preclinical animal disease models and the phase 1 study results lend strong support to clinical development for these clinical indications,” said Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen.

via Excellent Stem Cell Mobilization and Safety Profile for TG-0054.

GCKO,GVBP,NPDT,OGNG Wall Street News Alert

In BUSINESS OF STEM CELLS on September 14, 2009 at 11:06 am
NovaGen_Image01

GENova Biotherapeutics

GENova Biotherapeutics, Inc. (OTCBB: GVBP | Quote | Chart | News | PowerRating) up 17.8% on 39 million shares traded.

breast reconstructionOn Sept 10, 2009 GENova Biotherapeutics, Inc. a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, recently announced it has filed a patent for a potential blockbuster drug target that combats breast cancer. The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.

breast cancer cell

breast cancer cell

This novel approach – using proteins to stop cancer – is based on recent discoveries that indicate that most tumors are derived from a cancer stem cell. The technology behind Tetanolic acid involved identifying specific characteristics of these cancer stem cells and then tailoring a lipid (Tetanolic acid) that can identify these characteristics and then attack the malignant cells whilst leaving healthy cells intact. This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, with no side effects, and no harm to surrounding healthy tissues.

chemotherapy

chemotherapy

“This target has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy,” says Aaron Whiteman for GENova.

Worldwide, breast cancer is the fifth most common cause of cancer death, and is the most common cancer (and cause of cancer death) in women. The demand for new and better treatments for the disease is as urgent as ever.

via GCKO,GVBP,NPDT,OGNG Wall Street News Alert: Stock on the Move: GCKO – September 10, 2009.

Geron Clone? SEC says CellCyte Genetics lied to inflate stock price

In BUSINESS OF STEM CELLS on September 9, 2009 at 7:23 am

SEC: Bothell biotech firm lied to inflate stock price

By LEVI PULKKINENSEATTLEPI.COM STAFF

Federal regulators filed complaints Tuesday against (CellCyte Genetics Corp.) a Bothell-based biotechnology company, saying management of the firm defrauded investors by inflating claims about a stem cell technology it was developing.

In a statement to media, a Securities and Exchange Commission spokesperson alleged that CellCyte Genetics Corp. misled investors into believing the technology was headed for human trials when in fact the company’s product remained in the early stages of development.

SEC officials allege stock promoters hired by CellCyte then spread the false information to investors, driving the stock price to $7.50-a-share before it plummeted back to less than a dime.

The complaints, filed in federal district court in Seattle, allege that in multiple public filings with the SEC and in other investor materials CellCyte falsely claimed it had received U.S. Food and Drug Administration approval to begin human clinical trials with a special stem cell compound to repair the heart, the spokesperson said.

The SEC alleges that CellCyte did not know how to properly formulate the stem cell compound, had never tried experiments with the compound to repair organs and had not satisfied any of the FDA requirements to begin human clinical trials.

In addition to the corporation, the SEC named in the suit CellCyte’s then-Chief Scientific Officer Ronald Berninger, of Mukilteo, who allegedly approved or participated in the drafting of false and misleading statements.

CellCyte and Berninger agreed to a settlement, without admitting or denying the SEC’s allegations, in which they each consented to a permanent injunction, according to the news statement. Berninger also agreed to pay a $50,000 penalty and be barred from serving as an officer or director of a public company for five years.

Speaking Tuesday, CellCyte attorney Steve Fogg noted that the company did not pay a financial penalty and emphasized that the decision to settle with the SEC carried no admittion of guilt. Fogg said the company is no longer pursuing the technology at issue in the complaint.

“Given that they’re moving forward with a separate technology, it just made sense to settle this lawsuit,” said Fogg, adding that “nobody cashed in on CellCyte stock who was an officer or director of CellCyte.”

In a separate action, the SEC has accused ex-CellCyte CEO Gary Reys, of Freeland, of approving the company’s fraudulent SEC filings. Federal regulators are seeking injunctive relief, a monetary penalty and an order barring Reys from serving as an officer or director of a public company.

A few other sources of this info:

SEC Whacks CellCyte Genetics & Bosses
Courthouse News Service – ‎29 minutes ago‎ – SEATTLE (CN)
SEC: Bothell biotech co lied about breakthrough to inflate stock price
KOMO News – Martha Kang – ‎6 hours ago‎ – SEATTLE
SEC accuses CellCyte Genetics, former top execs of fraud
TechFlash – Eric Engleman – ‎8 hours ago‎
SEC Charges CellCyte With Stem Cell Fraud
Xconomy – Luke Timmerman – ‎14 hours ago‎
SEC sues CellCyte, former execs for lying to investors
FierceBiotech – Calisha Myers – ‎14 hours ago‎
SEC accuses CellCyte, execs of fraud
Bizjournals.com – ‎14 hours ago‎
SEC Charges Seattle-Area Biotech Company With Fraudulently Hyping
PharmaLive.com (press release) – ‎15 hours ago‎
BRIEF-US SEC charges CellCyte for fraudulently touting stem cell
Forbes – Julie Vorman – ‎16 hours ago‎
SEC sues CellCyte and its executives
Seattle Times – ‎17 hours ago‎

StemCells Inc’s (NASD: STEM) Advancement

In BUSINESS OF STEM CELLS on September 3, 2009 at 12:48 pm

stemcellslogoStemCells Inc’s (NASD: STEM) announced a significant advance in its stem cell therapeutic program.  Positive results from a study of the company’s HuCNS-SC cells (purified human neural stem cells) were published as the cover story in the latest issue of Cell Stem Cell, a leading scientific journal focused in the area of stem cells.

The findings of this study represent a key advance in the evaluation of stem cells as potential therapies for human diseases as it demonstrates for the first time that StemCells’ HuCNS-SC cells are able to delay the loss of motor function in a mouse model of NCL.  The company has already demonstrated that HuCNS-CS has a favorable safety profile in human patients with NCL (Phase 1 study results announced in June 2009).  These latest study results suggest that HuCNS-SC cells may ultimately represent a breakthrough treatment for neurodegenerative diseases such as NCL for which there are currently no cures.

via http://www.stemcellsinc.com/news/090903a.html

Mayo Clinic + stem cell biotech

In STEM CELLS IN THE NEWS on September 2, 2009 at 11:45 am

Kiger’s Notebook – By Jeff Kiger, Post-Bulletin business columnist

September 01, 2009

Mayo Clinic-linked stem cell biotech = “Tremendous potential”

I’ve written about Cardio3, a Belgium biotech that is using Mayo Clinic research as part of its stem cell-based cardiac treatment, a few times before here and here.Today the company kicked out a release about its presentation at the European Society of Cardiology Congress in Barcelona, Spain. Here a little from the release:

————–

A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient’s own cells into ‘cardiopoietic’ cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure…

via Postbulletin.com: Rochester, MN.

Russia’s first biotechnology IPO – STEM CELL STORAGE

In BUSINESS OF STEM CELLS on August 31, 2009 at 11:38 am

Investors look for upside as stem cell specialists prepare to list

31 August, 2009, 10:24

The Institute of Human Stem Cells is about to see one of Russia’s first biotechnology IPO’s in its attempt to boost the Russian stem cell storage market.

Finding a cure for previously incurable diseases – stem cell technology is pushing back the frontiers of medicine. Just how the potential of stem cell technology can be practically utilized is still undefined, but its promise is already obvious .

Stem cells are stored in stem cell banks – the Institute of Human Stem Cells in Moscow has over 50% of the Russian market.

Compared to other countries, the market has a vast growth potential, and the institute has formed a company to market its services. It’s storing stem cells and using them to develop new treatment methods.

The company is preparing for an IPO in the autumn, and is hoping to float from 15 to 25% of its shares to raise just under $5 million dollars, according to Head, Artur Isaev.

“Out cash flow comes from storing stem cells, but we also have an R and D section where we work on developing drugs. Our aim is to use the material in creating drugs and methods for curing certain diseases. If we succeed in that – our capitalisation could grow many- fold.”

via Investors look for upside as stem cell specialists prepare to list – RT.

DARA, ASC, ICTY, LDSR, CMLS, ONT

In BUSINESS OF STEM CELLS on August 26, 2009 at 7:08 pm

DARA BIOSCIENCES INCORPORATED (NASDAQ: DARA) “Up 31.24% on Wednesday” Detailed Quote: http://www.otcpicks.com/quotes/DARA.php

stemcells_money1DARA BioSciences Inc. (“DARA”) is a Raleigh, North Carolina based development-stage pharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND’s (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis.

DARA News: August 4 – DARA BioSciences, Inc. and America Stem Cell, Inc. Collaborate On Stem Cell Research DARA BioSciences, Inc. (Nasdaq: DARA) announced that the Company is collaborating with America Stem Cell (“ASC”) to expand on observations from recent preclinical studies showing that dipeptidylpeptidase (DPPIV) inhibitors improve the efficiency of hematopoietic stem cell (HSC) transplants. HSC transplants are used as a therapeutic approach for many malignant and non-malignant hematological disorders.

ASC will expand on these previous observations with preclinical studies utilizing potent and selective DPPIV inhibitors obtained from DARA BioSciences. The goal of this collaboration is to accelerate the translation of this approach to the clinic for the benefit of many patients in need of a HSC transplant.

ABOUT AMERICA STEM CELL, INC.

America Stem Cell, Inc. (“ASC”) is a privately held biotechnology company based in Carlsbad, CA, and is dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cells. The Company possesses two key technology platforms – ASC-101 and ASC-201 – that are designed to improve the engraftment of stem cells to target organs and increase their therapeutic potential.

via ICTY, LDSR, CMLS, ONT, DARA, August 6 Stocks to Watch from OTCPicks.com.

Patent Reform Battle Pits Biotech against High-Tech. Genetic Engineering & Biotechnology News – Biotechnology from Bench to Business

In ALL ARTICLES, BUSINESS OF STEM CELLS on March 6, 2009 at 5:12 pm

stemcells_money1

Patent Reform Battle Pits Biotech against High-Tech

GEN News Highlights – Mar 6 2009, 11:06 AM EST

Not many issues bring together biotech entrepreneurs and the teamsters, while pitting those life-sciences innovators against their fellow Silicon Valley and Cambridge denizens in the high-tech industry. Patent reform does, though, and it’s making its way through Congress once again with the introduction of the Patent Reform Act of 2009.

Although both are in the business of innovation, the way they build products is very different. Hence, they are at odds over intellectual property (IP) rules. To sum up their differences, powerhouse high-tech companies see themselves as potential infringers, while biotech companies’ worries are those of patent holders.

High tech companies use hundreds, sometimes thousands of components in a single product, and each of these may be subject to a patent. If one of those components infringes on a patent, the high-tech company would prefer that any damages awarded be apportioned, i.e., based on the percentage contribution of the infringing component to the product and not based on the value of the product itself.

The high-tech industry has also been plagued by so-called patent trolls, people or companies that file or acquire patents with no intention to market a product. The key court cases here involved a $612 million judgment for an infringing component of the Blackberry device.

Biotech companies have a different business model and very different IP concerns. They typically develop a drug with one active ingredient, covered by perhaps a composition patent and a method-of-use patent. These companies support strong patents with heavy penalties for infringement.

via News: Patent Reform Battle Pits Biotech against High-Tech. Genetic Engineering & Biotechnology News – Biotechnology from Bench to Business.

SCTPF,SSS Stem Cell Therapeutics Corp. Announces Issuance of Stock Options

In ALL ARTICLES, STEM CELLS IN THE NEWS on February 25, 2009 at 11:31 am

Stem Cell Therapeutics Corp. Announces Issuance of Stock Options

Wed. February 25, 2009; Posted: 08:30 AM

CALGARY, ALBERTA, Feb 25, 2009 (Marketwire via COMTEX) — SSS | Quote | Chart | News | PowerRating — Stem Cell Therapeutics Corp. (the “Company” or “SCT”) (TSX VENTURE:SSS) announces the issuance of stock options to officers and directors of the Company…

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The Company’s programs aim to repair neurological function lost due to disease or injury. SCT’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.

via SCTPF,SSS Stem Cell Therapeutics Corp. Announces Issuance of Stock Options.

%d bloggers like this: